세계의 분지병변 시장 : 시장 규모, 쉐어, 동향 분석(용도별, 지역별), 부문별 예측(2025-2030년)

Bifurcation Lesions Market Growth & Trends:

The global bifurcation lesions market size is expected to reach USD 3.5 billion by 2030, registering a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological developments and supportive government initiatives for reimbursement are likely to drive the market during the forecast period.

The increasing geriatric population and unhealthy lifestyle are responsible for growth in the incidence of cardiovascular disorders. Furthermore, an increase in approval & commercialization of innovative devices and the expected entry of new devices for the treatment of bifurcation lesions in the coming years are likely to drive the market.

In addition, factors such as rising affordability, increase in demand for minimally invasive procedures, and growing medical tourism are also boosting demand for bifurcation lesions procedures across the globe. According to various studies, procedures for coronary bifurcation lesions comprise approximately 20% of total percutaneous coronary interventions.

Bifurcation Lesions Market Report Highlights:

• Increase in the commercialization of devices for bifurcation lesions and investments by industry players for R&D are the factors expected to boost the market, resulting in an anticipated CAGR of around 6.0% from 2025 to 2030
• The coronary vascular segment accounted for the maximum share of the market in 2024 due to the presence of complex vascular network in heart, increased availability of devices, and rise in awareness regarding surgical interventions for bifurcation lesions.
• The peripheral vascular segment is likely to witness lucrative growth in the coming years due to an increase in investments by industry players for the development of devices for peripheral application and advancements in diagnostics facilitating accurate detection of plaque.
• Geographically, North America held the largest share of the bifurcation lesions market in 2024. It is anticipated to maintain its dominance in the coming years due to increasing demand for drug-eluting stents, commercialization of devices for bifurcation lesions, and the local presence of major market players.
• The Asia Pacific is expected to observe the fastest growth over the next decade owing to improvement in healthcare infrastructure, medical tourism, and a rise in investments by market players in the region.
• Some of the key players in the market are Abbott; Boston Scientific Corporation; Cardinal Health; Medtronic; Johnson & Johnson Services, Inc.; C. R. Bard, Inc.; Spectranetics; and Terumo Medical Corporation. Tryton Medical, Inc. developed the Tryton Side Branch Stent with a balloon-expandable, single-wire stent delivery system that can be deployed in the side branch artery for treatment of bifurcation lesions. The device is available in the U.S. and Europe as well as Middle East & Africa.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Regional scope
  • 1.2.3. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity price analysis (Model 1)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application Segment
  • 2.2.2. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Bifurcation Lesions Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of congenital heart disease
    • 3.2.1.2. Increasing number of CVD incidence
    • 3.2.1.3. Increasing awareness among the population
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment
    • 3.2.2.2. Limited awareness and adoption
• 3.3. Bifurcation Lesions Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Bifurcation Lesions Market: Application Estimates & Trend Analysis

• 4.1. Bifurcation Lesions Market: Application Dashboard
• 4.2. Bifurcation Lesions Market: Application Movement Analysis
• 4.3. Bifurcation Lesions Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 4.4. Coronary
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. Peripheral
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Bifurcation Lesions Market: Regional Estimates & Trend Analysis by Application, and Region

• 5.1. Global Bifurcation Lesions Market: Regional Dashboard
• 5.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 5.3. North America
  • 5.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.3.2. U.S.
    • 5.3.2.1. Key country dynamics
    • 5.3.2.2. Regulatory framework/ reimbursement structure
    • 5.3.2.3. Competitive scenario
    • 5.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.3. Canada
    • 5.3.3.1. Key country dynamics
    • 5.3.3.2. Regulatory framework/ reimbursement structure
    • 5.3.3.3. Competitive scenario
    • 5.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.3.4. Mexico
    • 5.3.4.1. Key country dynamics
    • 5.3.4.2. Regulatory framework/ reimbursement structure
    • 5.3.4.3. Competitive scenario
    • 5.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
• 5.4. Europe
  • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.4.2. UK
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.3. Germany
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.4. France
    • 5.4.4.1. Key country dynamics
    • 5.4.4.2. Regulatory framework/ reimbursement structure
    • 5.4.4.3. Competitive scenario
    • 5.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.5. Italy
    • 5.4.5.1. Key country dynamics
    • 5.4.5.2. Regulatory framework/ reimbursement structure
    • 5.4.5.3. Competitive scenario
    • 5.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.6. Spain
    • 5.4.6.1. Key country dynamics
    • 5.4.6.2. Regulatory framework/ reimbursement structure
    • 5.4.6.3. Competitive scenario
    • 5.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.7. Sweden
    • 5.4.7.1. Key country dynamics
    • 5.4.7.2. Regulatory framework/ reimbursement structure
    • 5.4.7.3. Competitive scenario
    • 5.4.7.4. Sweden market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.8. Norway
    • 5.4.8.1. Key country dynamics
    • 5.4.8.2. Regulatory framework/ reimbursement structure
    • 5.4.8.3. Competitive scenario
    • 5.4.8.4. Norway market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.4.9. Denmark
    • 5.4.9.1. Key country dynamics
    • 5.4.9.2. Regulatory framework/ reimbursement structure
    • 5.4.9.3. Competitive scenario
    • 5.4.9.4. Denmark market estimates and forecast, 2018 - 2030 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5.2. China
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. China market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5.3. Japan
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5.4. India
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. India market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5.5. Australia
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5.6. Thailand
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Thailand market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.5.7. South Korea
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Regulatory framework/ reimbursement structure
    • 5.5.7.3. Competitive scenario
    • 5.5.7.4. South Korea market estimates and forecast, 2018 - 2030 (USD Million)
• 5.6. Latin America
  • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Brazil
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.6.3. Argentina
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework/ reimbursement structure
    • 5.6.3.3. Competitive scenario
    • 5.6.3.4. Argentina market estimates and forecast, 2018 - 2030 (USD Million)
• 5.7. MEA
  • 5.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Saudi Arabia
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7.3. South Africa
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework/ reimbursement structure
    • 5.7.3.3. Competitive scenario
    • 5.7.3.4. South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7.4. UAE
    • 5.7.4.1. Key country dynamics
    • 5.7.4.2. Regulatory framework/ reimbursement structure
    • 5.7.4.3. Competitive scenario
    • 5.7.4.4. UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • 5.7.5. Kuwait
    • 5.7.5.1. Key country dynamics
    • 5.7.5.2. Regulatory framework/ reimbursement structure
    • 5.7.5.3. Competitive scenario
    • 5.7.5.4. Kuwait market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. List of key distributors and channel partners
  • 6.3.2. Key customers
  • 6.3.3. Key company market share analysis, 2023
  • 6.3.4. Boston Scientific Corp.
    • 6.3.4.1. Company overview
    • 6.3.4.2. Financial performance
    • 6.3.4.3. Product benchmarking
    • 6.3.4.4. Strategic initiatives
  • 6.3.5. Abbott
    • 6.3.5.1. Company overview
    • 6.3.5.2. Financial performance
    • 6.3.5.3. Product benchmarking
    • 6.3.5.4. Strategic initiatives
  • 6.3.6. Cardinal Health
    • 6.3.6.1. Company overview
    • 6.3.6.2. Financial performance
    • 6.3.6.3. Product benchmarking
    • 6.3.6.4. Strategic initiatives
  • 6.3.7. Medtronic
    • 6.3.7.1. Company overview
    • 6.3.7.2. Financial performance
    • 6.3.7.3. Product benchmarking
    • 6.3.7.4. Strategic initiatives
  • 6.3.8. C. R. Bard, Inc.
    • 6.3.8.1. Company overview
    • 6.3.8.2. Financial performance
    • 6.3.8.3. Product benchmarking
    • 6.3.8.4. Strategic initiatives
  • 6.3.9. Johnson & Johnson Services, Inc.
    • 6.3.9.1. Company overview
    • 6.3.9.2. Financial performance
    • 6.3.9.3. Product benchmarking
    • 6.3.9.4. Strategic initiatives
  • 6.3.10. Spectranetics
    • 6.3.10.1. Company overview
    • 6.3.10.2. Financial performance
    • 6.3.10.3. Product benchmarking
    • 6.3.10.4. Strategic initiatives
  • 6.3.11. Terumo Medical Corp.
    • 6.3.11.1. Company overview
    • 6.3.11.2. Financial performance
    • 6.3.11.3. Product benchmarking
    • 6.3.11.4. Strategic initiatives
  • 6.3.12. Tryton Medical Inc.
    • 6.3.12.1. Company overview
    • 6.3.12.2. Financial performance
    • 6.3.12.3. Product benchmarking
    • 6.3.12.4. Strategic initiatives